Spike Protein News and Research

RSS

Designing a prototype spike protein vaccine for SARS-CoV-2

A recent study published on the preprint server bioRxiv in June 2020 reports the development of a prototype vaccine containing multiple antigenic sites, based on the spike protein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that is causing the current COVID-19 pandemic. If successful, this could lead to the development of an effective, non-allergenic vaccine that induces both humoral and cellular immunity.

4 Jun 2020

Comparing genomes to understand how mutations affect the COVID-19 pandemic

Now, a new study by researchers at the Massachusetts Institute of Technology and the Center for Computational Biology, Flatiron Institute and published online on the bioRxiv preprint server describes how the use of comparative genomics helps to identify protein-coding and non-coding functional genes.

4 Jun 2020

SARS-CoV-2 gene deletions may cause milder infections and increase human-to-human transmission

In their recent paper released on the bioRxiv preprint server, a research group from Spain demonstrated how genome changes and deletions in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could represent a strategy of natural selection used for lessening the impact of infection in order to increase viral transmission potential.

4 Jun 2020

Alpaca-derived antiviral agent neutralizes SARS-CoV-2

Researchers at Karolinska University Hospital and the University of Cape Town have identified an antibody fragment that targets the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein and potently neutralizes the virus.

4 Jun 2020

Siemens receives FDA approval for SARS-CoV-2 antibody test

Siemens Healthineers has announced that the U.S. Food and Drug Administration (FDA) had issued an Emergency Use Authorization for its total antibody test to detect the presence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, including Immunoglobulin M (IgM) and Immunoglobulin G (IgG) in the blood.

3 Jun 2020

A vectored vaccine candidate against SARS-CoV-2

The current pandemic of COVID-19 is caused by the severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), a betacoronavirus similar to that which caused the SARS-CoV and MERS-CoV earlier. Scientists are pursuing therapeutic drugs and vaccines to counter the relentless spread of the virus, but so far, none has been established to be effective. However, several are in clinical trials in various parts of the world.

2 Jun 2020

Study reveals how essential SARS-CoV-2 protein can be stabilized and scaled for production

A research group from the University of Texas in Austin described a high-yield production of a stabilized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S-protein) that may accelerate the development of vaccines and diagnostic tests. This methodological 'tour de force' paper is currently available on the bioRxiv* preprint server.

1 Jun 2020

Genetic shuffling and evolutionary selection may have led to SARS-CoV-2 emergence

A combination of genetic shuffling and evolutionary selection of near-identical genetic sequences among specific bat and pangolin coronaviruses may have led to the evolution of SARS-CoV-2 and its introduction into humans, a new study suggests.

30 May 2020

Origin of SARS-CoV-2 virus well-suited to jump from animals to humans

A team of scientists studying the origin of SARS-CoV-2, the virus that has caused the COVID-19 pandemic, found that it was especially well-suited to jump from animals to humans by shapeshifting as it gained the ability to infect human cells.

30 May 2020

Genomic variation and descent of SARS-CoV-2 strains in India

The pandemic of COVID-19 that is still affecting over 188 countries and territories the world over has taken over 359,000 lives in just under five months, while affecting at least 5.8 million people. Different strains have diverged from the original strain detected in Wuhan, China.

28 May 2020

Ferritin heavy chain protein shows promise as a potential SARS-CoV-2 vaccine or antiviral

A new study published on the online preprint server bioRxiv in May 2020 reports the construction and testing of a new ferritin-based antigen-bearing protein that has biological activity towards the ACE2 receptor. This could indicate its potential for development as a vaccine or antiviral.

28 May 2020

A closer look at TMPRSS2: This could help treat COVID-19

The transmembrane protease serine-type 2 (TMPRSS2) protein plays a key role in COVID-19 infection since it primes the viral spike protein to allow viral entry into the target cell. A new study by researchers at Imperial College London and published on the preprint server bioRxiv in May 2020 describes the protein, which could be an attractive drug target to help manage COVID-19.

28 May 2020

SignalChem Biotech Inc. launches COVID-19 elisa kits for diagnostic research

SignalChem, a global leader in cell signaling and protein engineering, has been conducting research on new coronaviruses since the outbreak of the virus.

From SignalChem Biotech Inc. 28 May 2020

Measuring the binding of SARS-CoV-2 antibodies to the COVID spike protein using SPR

Ryan Denomme, the CEO of Nicoya, speaks to News-Medical on their SARS-CoV-2 research using their SPR technology.

From Nicoya Lifesciences 28 May 2020

Clinical trial of COVID-19 vaccine starts in Australia

Over 100 candidate vaccines are being explored as a means of ending the COVID-19 pandemic. Eight of these have already made it to clinical trials in humans, and another 94 are in the pre-clinical evaluation stage.

27 May 2020

Study shows children and adults have a comparable expression of SARS-CoV-2 entry-related genes

A recent paper by researchers from China demonstrated comparable expression levels of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry mediators in adults and children, suggesting that previously implied difference in viral-entry associated genes is likely not responsible for milder symptoms in children. The study is currently available on the medRxiv preprint server.

27 May 2020

Identifying the Starting Points for COVID19 Treatment

News-Medical spoke to researchers from the German Primate Center on their research in determining the activation sequence of the SARS-CoV-2 virus.

27 May 2020

CanSino's potential coronavirus vaccine triggers immune response in clinical trial

Scientists across the globe are racing to develop a vaccine that can provide protection against coronavirus disease (COVID-19). An effective and safe vaccine would curb not only the current coronavirus pandemic but also prevent future outbreaks

27 May 2020

New data may help understand the evolution of Austrian SARS-CoV-2 strains

216 SARS-CoV-2 genome sequences have now been completed and released in the framework of the "Mutational Dynamics of SARS-CoV-2 in Austria" project from CeMM, the Research Center for Molecular Medicine of the Austrian Academy of Sciences, in close collaboration with the Medical University of Vienna, the Medical University of Innsbruck and the Austrian Agency for Health and Food Safety (AGES).

27 May 2020

Many different T cell receptors recognize SARS-CoV-2 antigenic sites

The global COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is spreading over the world. However, not much is known about how the adaptive immune response kicks in following the viral challenge. This knowledge is crucial to predicting the efficacy of a vaccine and estimating the chances of reinfection.

26 May 2020